BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced its support for the Oley Foundation’s second annual HPN Awareness Week, which is held August 5-11, 2012. HPN, or Home Parenteral Nutrition, is an intravenous fluid for patients who are unable to obtain enough nutrients to survive through a normal diet, most often due to digestive disorders such as short bowel syndrome. The goal of the observance is to bring attention to the HPN community and help its members realize that they can lead enriched and fulfilling lives, despite the challenges they face.
HPN is often administered seven days per week and in extreme cases, some patients require treatment through an IV for 24 hours a day. Most often, HPN is administered overnight for 10 to 12 hours, which can disrupt sleep, cause frequent visits to the bathroom, and interrupt daytime activities if a longer period of treatment is required. However, HPN is important to those who depend on it for essential nutrients required to live. And, for some patients, HPN may help them live more active daily lives.
“We commend the Oley Foundation for its ongoing service to patients who rely on parenteral nutrition and support the organization's efforts to encourage this community of patients to live life to the fullest,” said Francois Nader, MD, president and chief executive officer of NPS Pharmaceuticals.
Throughout this week, the HPN community is encouraged to help spread the word about the importance their treatment plays in their lives by being active in relevant online communities, including the Oley Foundation Support Community Online Forum and the Oley Facebook page. Additionally, patients are encouraged to share their stories with local media, upload videos to YouTube or blog about their experiences.
About The Oley Foundation
The Oley Foundation enriches the lives of those requiring home intravenous and tube feeding through education, outreach and networking and provides its 12,000 members with critical information on topics such as research, health insurance, and medical advances. The Foundation is also a source of support, helping consumers on home tube and IV feeding overcome challenges such as their inability to eat and altered body image. All Oley programs are offered free of charge to consumers and their families.
About Short Bowel Syndrome
Short bowel syndrome, or SBS, is a highly disabling condition that can impair a patient's quality-of-life and lead to serious life-threatening complications. SBS typically arises after extensive resection of the bowel due to Cohn’s disease, ischemia or other conditions. SBS patients often suffer from malnutrition, severe diarrhea, dehydration, fatigue, osteopenia, and weight loss due to the reduced intestinal capacity to absorb nutrients, water, and electrolytes. The usual treatment for SBS is nutritional support, including parenteral nutrition or intravenous fluids (parenteral support) to supplement and stabilize nutritional needs.
Although parenteral support can meet basic nutrition and fluid requirements by delivering them intravenously, it does not improve the body's own ability to absorb nutrients. Parenteral support is also associated with serious complications, such as infections, blood clots or liver damage, and the risks increase the longer patients are on it. Patients on parenteral support often experience a poor quality-of-life with difficulty sleeping, frequent urination and loss of independence.
There are an estimated 10,000 to 15,000 SBS patients in the U.S. who are dependent on parenteral support.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex® (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natpara™ (recombinant human parathyroid hormone (rhPTH [1-84]) in adult hypoparathyroidism. NPS’ earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed (acquired by Takeda Pharmaceutical Company Limited).
“NPS,” “NPS Pharmaceuticals,” “Gattex,” and “Natpara” are the company’s trademarks. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated to the company’s business include, but are not limited to, the risks associated with any failure by the company to successfully complete its preclinical and clinical studies within the projected time frames or not at all, the risk of not gaining marketing approvals for Gattex and Natpara, the risks associated with the company’s strategy, as well as other risk factors described in the company’s periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information.